Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

BACKGROUND: TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with serum anti-p53 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Kumekawa, Yosuke, Ogura, Mariko, Ozaka, Masato, Matsusaka, Satoshi, Chin, Keisho, Yamamoto, Noriko, Mizunuma, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618932/
https://www.ncbi.nlm.nih.gov/pubmed/26490659
http://dx.doi.org/10.1186/s12885-015-1751-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618932/
https://www.ncbi.nlm.nih.gov/pubmed/26490659
http://dx.doi.org/10.1186/s12885-015-1751-6

Ejemplares similares